Grail Publishes PATHFINDER 2 Presentation on Multi-Cancer Detection in Adults Aged 65 and Older
Bitget2026/10/27 23:51- Grail published a medical research presentation on PATHFINDER 2 results for its Galleri multi-cancer early detection test in adults aged 65 and older.
- The test detected 41.9% of cancers diagnosed within 12 months, with 99.44% specificity.
- Positive predictive value was 56.9%, with cancer confirmed in 116 of 204 participants testing positive.
- Adding Galleri to USPSTF grade A/B screening increased screen-detected cancers 9.9-fold, to 129 from 13.
- Among newly diagnosed primary cancers detected by Galleri, 69.3% were stage I-III; 84.3% of those received curative-intent treatment.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Apple plans to further reduce employees' AI usage limits
Intel's decline narrows, CEO spends nearly 10 million dollars to increase stock holdings
Intel disclosed that CEO Pat Gelsinger purchased 150,000 shares of Intel common stock on the open market on November 2nd, at a weighted average price of $64.7312 per share, with a transaction amount of approximately $9.71 million. The purchase was made through a family trust, and after the transaction, the trust's Intel holdings increased to 1.4647 million shares, up around 11.4% from before the transaction. Following the announcement, Intel’s share price briefly rallied, narrowing its decline to 1.2% before retreating again.
Crypto prices
More
